Investors are awaiting the company's fourth-quarter results, scheduled for February 6, for an update on the China issue.

AstraZeneca PLC AZN shares inched down 0.09% to £111.70 Tuesday, on what proved to be an all-around favorable trading session ...

Enhertu’s label expansion comes on the heels of the FDA’s approval of the partners' Datroway for a related type of breast ...

FDA approves Enhertu for metastatic breast cancer with HER2-low or HER2-ultralow expression after showing significant ...

In a report released yesterday, Luisa Hector from Berenberg Bank maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Shares of AstraZeneca PLC AZN rallied 1.18% to £111.80 Monday, on what proved to be an all-around positive trading session ...

New approval brings the medicine to an earlier treatment setting and a broader patient population.

MULTINATIONAL pharmaceutical firm AstraZeneca (AZ) wants to conduct the majority of its clinical trials in the Philippines, ...

AstraZeneca invests $570 million in Canada, expands facilities, and boosts R&D efforts, aiming to deliver 20 new medicines ...

The U.S. Food and Drug Administration has approved AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) ENHERTU ...

AstraZeneca will expand the its global R&D hub in Mississauga. This $820 million investment underscores Ontario ’s growing ...